Such an assumption is supported by the higher circulating myostatin levels in BMD compared with DMD, and experimentally by the stronger effect of anti-myostatin therapy in mdx mice if complemented by dystrophin restoration through exon skipping14, 32. The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.